All > Graft Vs Host Disease

[18F]F-Ara-G for Graft-versus-Host Disease

Stanford Hospital, Stanford, CA
Graft-versus-Host Disease[18F]F-Ara-G - Drug
Eligibility
18+
All Sexes

Study Summary

This trial is testing whether a PET scan using a tracer called [18F]F-AraG can help identify sites of Graft Versus Host Disease (GVHD) in patients who are likely to have the disease or are at high risk of developing it.

Eligible Conditions
  • Graft-versus-Host Disease

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

1
GDC-8264, Dose 1
1
Neihulizumab (AbGn-168H)
1
Steroid Therapy

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Duration of the follow up will extend to 6 months post final scan for all aGVHD subjects by chart review.

Month 6
Development of aGVHD
Severity/score of aGVHD
Day 7
Healthy subject

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
GDC-8264, Dose 1
1
Neihulizumab (AbGn-168H)
1
Steroid Therapy

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

3 Treatment Groups

Highly suspected to already have aGVHD
1 of 3
Healthy Subjects
1 of 3
High risk of developing aGVHD
1 of 3

Experimental Treatment

30 Total Participants · 3 Treatment Groups

Primary Treatment: [18F]F-Ara-G · No Placebo Group · Phase 1

Highly suspected to already have aGVHD
Drug
Experimental Group · 1 Intervention: [18F]F-Ara-G · Intervention Types: Drug
Healthy Subjects
Drug
Experimental Group · 1 Intervention: [18F]F-Ara-G · Intervention Types: Drug
High risk of developing aGVHD
Drug
Experimental Group · 1 Intervention: [18F]F-Ara-G · Intervention Types: Drug

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: duration of the follow up will extend to 6 months post final scan for all agvhd subjects by chart review.

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor
15 Previous Clinical Trials
267 Total Patients Enrolled
Stanford UniversityOTHER
2,222 Previous Clinical Trials
34,904,567 Total Patients Enrolled
Sanjiv Gambhir, M.D,, Ph.D.Principal InvestigatorStanford University

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Has [18F]F-Ara-G received authorization by the Food and Drug Administration?

"The [18F]F-Ara-G has been given an appraisal of 1, as the current trial is a Phase 1. This classification implies that there is only limited data proving its safety and efficacy." - Anonymous Online Contributor

Unverified Answer

What is the uppermost limit for enrollment in this experiment?

"Affirmative. Information hosted on clinicaltrials.gov reveals that this trial, which was originally posted in May of 2018, is looking for participants right now. The study will be recruiting 30 individuals at a single facility." - Anonymous Online Contributor

Unverified Answer

Is this trial currently in search of participants?

"Affirmative, according to clinicaltrials.gov this investigation is enrolling participants at present. It was first published on May 15th 2018 and modified most recently on March 7th 2022. 30 people need to be enlisted from one site for the study's success." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top